Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohn's & Colitis 360 · 01.01.2024 · 6 (1)
DOI: 10.1093/crocol/otae013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Crohn's & Colitis 360, online erschienen am 26.02.2024. Verfasst von Thea H Wiken und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departement of Gastroenterology, Oslo University Hospital, Ullevål, Oslo, Norway. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Oslo University Hospital.
Abstract (Originalsprache)
Background
Vedolizumab has since 2021 been available as a subcutaneous formulation. We aimed to assess 18-month drug persistence and possible predictive factors associated with discontinuation, safety, serum drug profile, drug dosing, and disease activity in a real-world cohort of patients with inflammatory bowel disease switched from intravenous to subcutaneous vedolizumab maintenance treatment.
Methods
Eligible patients were switched to subcutaneous vedolizumab and followed for 18 months or until discontinuation of subcutaneous treatment. Data on preferred route of administration, adverse events, drug dosing, serum-vedolizumab, disease activity, fecal calprotectin, and C-reactive protein were collected. Persistence was described using Kaplan–Meier analysis. The impact of clinical and biochemical variables on persistence was analyzed with Cox proportional hazard models.
Results
We included 108 patients, and the estimated 18-month drug persistence was 73.6% (95% CI [64.2–80.1]). Patients in clinical remission at switch were less likely to discontinue SC treatment (HR = 0.34, 95% CI [0.16–0.73], P = .006), and patients favoring intravenous treatment at switch were almost 3 times more likely to discontinue (HR = 2.78, 95% CI [1.31–5.90], P = .008). Four patients discontinued subcutaneous vedolizumab due to injection site reactions. At 18 months, 88% of patients administered subcutaneous vedolizumab with an interval of ≥ 14 days, and serum-vedolizumab was 39.1 mg/L. Disease activity was stable during follow-up.
Conclusions
Three of the four patients remained on subcutaneous vedolizumab after 18 months, a large proportion received treatment at standard dosing intervals, and disease activity remained stable. This indicates that switching from intravenous to subcutaneous vedolizumab treatment is convenient and safe.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Departement of Gastroenterology, Oslo University Hospital, Ullevål, Oslo, Norway.
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
- Department of Medical Biochemistry, Oslo University Hospital, Radiumhospitalet, Norway.
- Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway.
- Department of FOU and Gastroenterology, Østfold Hospital Trust, Kalnes, Norway.
ORCID-Profile: Thea H Wiken, Karoline Anisdahl, Lydia Buer, Milada Hagen, Bjørn A Moum, Asle W Medhus
Förderung
- Oslo University Hospital
Zitieren
APA
Wiken, T. H., Høivik, M. L., Anisdahl, K., Buer, L., Warren, D. J., Bolstad, N., Hagen, M., Moum, B. A., & Medhus, A. W. (2024). Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study. Crohn's & Colitis 360, 6(1). https://doi.org/10.1093/crocol/otae013
Vancouver
Wiken TH, Høivik ML, Anisdahl K, Buer L, Warren DJ, Bolstad N, et al. Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study. Crohn's & Colitis 360. 2024;6(1). doi:10.1093/crocol/otae013
BibTeX
@article{Wiken2024,
author = {Wiken, Thea H and Høivik, Marte L and Anisdahl, Karoline and Buer, Lydia and Warren, David J and Bolstad, Nils and Hagen, Milada and Moum, Bjørn A and Medhus, Asle W},
title = {Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study},
journal = {Crohn's & Colitis 360},
year = {2024},
volume = {6},
number = {1},
doi = {10.1093/crocol/otae013}
}
EUVIMED